The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Combination therapies with immunosuppressive ... to standard cytotoxic therapy lupus nephritis, exerting significant antiproteinuric effects. Therapeutic drug level monitoring and vigilant follow ...

Fintel reports that on December 2, 2024, Piper Sandler initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) ...

Kidney inflammation caused by SLE is referred to as lupus nephritis ... The new drug is thought to have a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell ...

The goal of lupus nephritis treatments is to preserve kidney function and reduce morbidity and mortality of chronic kidney ...

Pathology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium Correspondence to Professor F A Houssiau, Rheumatology Department, Cliniques ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...

We are grateful to our colleagues for their interest and thoughtful comments on our Seminar about systemic lupus erythematosus (SLE).1 We appreciate the remarks from Qihe Xu, and Thomas Pabst and ...

AstraZeneca's Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus (SLE) in the EU for more than 10 years. The European Commission has ...

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025Scott Wolchko To Retire as President and CEO after 10 years of Leadership in ...